NCT06965062 · RECRUITING
Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)
This trial is testing a surgical procedure that connects lymph nodes in the neck to nearby veins, with the goal of improving the brain's ability to drain waste proteins like amyloid and tau. Researchers in Singapore want to know if it is safe and whether it shows any early signs of slowing cognitive decline. This is a Phase N/A proof-of-concept study, meaning it is very early-stage — testing feasibility, not yet proving the procedure works.
You may qualify if
- Diagnosis of mild-moderate Alzheimer's disease (based on NIA-AA criteria);
- Mini-Mental State Examination (MMSE) score 10-22;
- Both participants and caregiver are able to understand English or Mandarin
- Ability to provide informed consent or have a legally authorised representative to provide informed consent;
- Good family support for post-treatment care and rehabilitation;
- Fit for general anaesthesia/deep sedation and surgery (ASA 1-2; excluding the diagnosis of Alzheimer's Disease).
You're excluded if
- Cognitive decline due to prior infection or autoimmune diseases;
- History of major cerebrovascular events or significant cardiovascular diseases;
- Inability to have the head turned passively by at least 40 degrees;
- Previous neck lymph node surgery or irradiation;
- Active infection or malignancy;
- Any contraindications to surgery or lumbar puncture
- Any contraindication to MRI/PET scan (eg. metallic implant that are not MRI-safe, known radiotracer allergy)
- Experimental Alzheimer's Disease treatment within the past 6 months. • Current use of monoclonal antibodies treatment (eg. lecanemab/donanemab)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-01-13